ArticleClinical cardiology2026
Prognostic Value of Cystatin C Across Ejection Fraction Spectrum in Heart Failure With Normal to Mild Renal Dysfunction Original Investigation.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCystatin C (CysC)'s predictive utility for long-term adverse outcomes in heart failure (HF) patients with normal to mild renal insufficiency remains unclear. This study investigates the relationship between CysC and adverse outcomes in HF patients across the whole ejection fraction (EF) spectrum with normal to mild renal insufficiency.
methodsIn this single-center cohort study, 637 HF patients with normal to mild renal insufficiency were categorized into reduced EF (HFrEF), mid-range EF (HFmrEF), and preserved EF (HFpEF) groups. Associations between natural log unit (CysC) and risks of all-cause mortality and HF rehospitalization were examined using Cox regression models. C-index, IDI, and NRI assessed the incremental prognostic value.
resultsOver a follow-up of 9.4 years, 271 patients died, and 330 were rehospitalized for HF. Multivariate Cox regression analysis indicated significant associations between elevated CysC levels and increased risks of all-cause mortality (HR = 1.99, 95% CI: 1.57-2.54) and HF rehospitalization (HR = 1.95, 95% CI: 1.57-2.42) across all patients. HR's for all-cause mortality observed for HFmrEF (HR 4.73, 95% CI: 2.08-10.74) and HFrEF (HR 15.11, 95% CI: 6.24-36.60) were higher compared to those for HFpEF patients (HR = 1.48, 95% CI 0.98-2.23), and CysC showed less prognostic impact on all-cause mortality in HFpEF patients. Including CysC in the MAGGIC risk score-based model provided additional prognostic value for all subjects, even with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels added.
conclusionsCysC is an independent risk factor for adverse outcomes in HF patients across EF spectrum with normal to mild renal insufficiency. Integrating CysC into the MAGGIC risk score-based model enhances its prognostic capability for predicting adverse outcomes in the general HF population. Its prognostic effect on all-cause mortality is limited in HFpEF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.